Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The malaria parasite Plasmodium vivax causes frequent, chronic infections that represent a major unrecognized burden on global health, according to a review by Kevin Baird of the Eijkman-Oxford Clinical Research Unit in Indonesia and Katherine Battle of the Institute for Disease Modeling in the United States

Young girl suffering from vivax malaria lying on a bed

In this review, Kevin Baird from EOCRU and Katherine Battle summarise evidence indicating that the global burden of malaria estimated from reported cases of acute attacks likely miss the widespread but more subtle harm done by chronic infection of P. vivax. Futhermore, P. vivax often affects impoverished communities where people face multiple health challenges. A recent study found that while P. falciparum is more likely to cause death within two weeks of diagnosis, patients with P. vivax were more than twice as likely to die over the long term. Chronic infections in people who are repeatedly exposed to P. vivax cause damage to the kidneys, brain, and circulatory system.

An improved understanding of the biology of P. vivax has recently revealed multiple factors that contribute to its toll on global health. The parasite can exist in the body at low levels that cause no symptoms, making it difficult to diagnose, but can still spread. Sub-Saharan Africa was once thought to be practically immune to P. vivax infection because most of the population lack the Duffy antigen, a molecule on the surface of red blood cells the parasite uses to invade. However, a recent study finds that P. vivax transmission is still widespread in this region. Additionally, there are two common genetic variations carried by part of the population that interfere with successful treatment of P. vivax malaria.

All these factors complicate efforts to estimate the full extent of P. vivax infections and control its spread. Baird and Battle conclude that the traditional approaches developed to combat P. falciparum in Africa are inadequate for P. vivax. Eliminating P. vivax will require different diagnostics, therapies and vector control strategies, and better data that reveal the true scope of the burden.

Read the publication 'The global burden of Plasmodium vivax malaria is obscure and insidious' on the PLOS Medicine website

The full story is available on the OUCRU website

Similar stories

Improving access to care for people in Vietnam impacted by Hepatitis C: dissemination workshop to share findings of OUCRU’s community-based participatory research

OUCRU and HCMC Hospital for Tropical Diseases host a one-day research dissemination workshop for policy, healthcare, community, and research stakeholders. The workshop is the culmination of an OUCRU project: “Community-based participatory research to promote engagement with underserved communities at risk of Hepatitis C virus in Ho Chi Minh City, Vietnam”.

The journey of dreams, improving engagement with underserved populations at risk for Hepatitis C in Vietnam.

OUCRU Public and Community Engagement team produced a video based on their project “Community-based participatory research to promote engagement with underserved communities at risk of Hepatitis C virus in Ho Chi Minh City, Vietnam”. This video was made by community members of the community-based participatory research to the project. The video is in Vietnamese with English subtitles

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Multidisciplinary dengue forecasting project launches in Vietnam

DART (Dengue Advanced Readiness Tools), is a new project supported by Wellcome to use climate data to better predict and prepare for infectious diseases outbreaks.

OUCRU’s Photographer In Residence Featured In The Lancet’s Highlights 2022

Photographs have the power to inform and engage viewers. Earlier this year, The Lancet invited submissions for Highlights, the publication’s annual photography competition. Highlights 2022 featured 14 winning photographs telling stories from a wide variety of health-related topics that captured the world’s attention in 2022. One of the powerful images selected was from Pearl Gan, OUCRU’s Photographer in Residence.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.